Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

Nilotinib has significant efficacy in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and in patients with CML-CP or CML in accelerated phase (CML-AP) after imatinib failure. We investigated the occurrence of cross-intolerance to nilotinib in imatinib-intolerant pati...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Cortes, Jorge E., Hochhaus, Andreas, le Coutre, Philipp D., Rosti, Gianantonio, Pinilla-Ibarz, Javier, Jabbour, Elias, Gillis, Kathryn, Woodman, Richard C., Blakesley, Rick E., Giles, Francis J., Kantarjian, Hagop M., Baccarani, Michele
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2011
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186645/
https://ncbi.nlm.nih.gov/pubmed/21467546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-11-318949
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak